Iodine-125 Seed Implantation (Permanent Brachytherapy) for Clinically Localized Prostate Cancer

摘要: From January 2004 to March 2007, 308 patients with clinically localized prostate cancer were treated using iodine-125 (125I) seed implantation (permanent brachytherapy) at Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences. We evaluated the treatments efficacy morbidity in 300 who followed up for more than 1 month after brachytherapy. Based on National Comprehensive Cancer Network (NCCN) guidelines, a volume less 40 ml transrectal ultrasound imaging classified as low or intermediate risk. The median patient age was 67 years (range 50 79 years), prostate-specific antigen (PSA) value before biopsy 6.95 ng/ml 1.13 24.7 ng/ml), 24.33 9.3 41.76 ml). follow-up 18 months 36 months) PSA levels decreased almost all Although 194 (64.7%) complained difficulty urination, pollakisuria/urgency, miction pain, and/or urinary incontinence, which might be associated radiation prostatitis during first brachytherapy, these symptoms gradually improved. 125I brachytherapy is safe effective within short-term follow up.